Post COVID-19 reboot of clinical trials in Asia Pacific
White Paper
Jul 09, 2020

The recent restrictions imposed by many countries in response to the recent COVID-19 outbreak has impacted ongoing clinical research, and restarting clinical trials is a critically important activity. IQVIA investigates how research sites are utilizing a variety of measures, including diagnostic tests, in an attempt to minimize risk of external transmission of the infection to staff and patients at the site.

You may also be interested in